GenMont Biotech Incorporation (3164.TW)
TWD 18.3
(-1.88%)
TWD 18.3
(-1.88%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 32.99 Million TWD | -42.1% |
| 2022 | 56.97 Million TWD | -49.64% |
| 2021 | 113.13 Million TWD | 85.82% |
| 2020 | 60.88 Million TWD | 5.98% |
| 2019 | 57.45 Million TWD | -63.64% |
| 2018 | 158.01 Million TWD | 246.53% |
| 2017 | 45.6 Million TWD | 119.33% |
| 2016 | -235.93 Million TWD | -140.68% |
| 2015 | -98.02 Million TWD | 74.61% |
| 2014 | -386.15 Million TWD | -1350.07% |
| 2013 | 30.89 Million TWD | 6.93% |
| 2012 | 28.89 Million TWD | -24.29% |
| 2011 | 38.15 Million TWD | -74.14% |
| 2010 | 147.54 Million TWD | 71.09% |
| 2009 | 86.23 Million TWD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 34.74 Million TWD | 1824.37% |
| 2024 Q2 | 14.67 Million TWD | -57.77% |
| 2023 Q2 | 2.88 Million TWD | -49.92% |
| 2023 Q3 | 23.87 Million TWD | 727.09% |
| 2023 FY | 32.99 Million TWD | -42.1% |
| 2023 Q4 | -2.01 Million TWD | -108.44% |
| 2023 Q1 | 5.76 Million TWD | -58.36% |
| 2022 Q4 | 13.84 Million TWD | 163.66% |
| 2022 FY | 56.97 Million TWD | -49.64% |
| 2022 Q3 | 5.25 Million TWD | -55.19% |
| 2022 Q2 | 11.71 Million TWD | -49.7% |
| 2022 Q1 | 23.29 Million TWD | -47.32% |
| 2021 Q1 | 30.6 Million TWD | 298.54% |
| 2021 FY | 113.13 Million TWD | 85.82% |
| 2021 Q4 | 44.22 Million TWD | 87.74% |
| 2021 Q3 | 23.55 Million TWD | 59.68% |
| 2021 Q2 | 14.75 Million TWD | -51.8% |
| 2020 Q1 | 8.91 Million TWD | 332.15% |
| 2020 Q2 | 15.14 Million TWD | 69.86% |
| 2020 Q3 | 29.14 Million TWD | 92.41% |
| 2020 FY | 60.88 Million TWD | 5.98% |
| 2020 Q4 | 7.67 Million TWD | -73.65% |
| 2019 FY | 57.45 Million TWD | -63.64% |
| 2019 Q1 | 41.16 Million TWD | 66.65% |
| 2019 Q3 | 15.95 Million TWD | 282.09% |
| 2019 Q2 | 4.17 Million TWD | -89.85% |
| 2019 Q4 | -3.84 Million TWD | -124.07% |
| 2018 Q1 | 4.05 Million TWD | 125.34% |
| 2018 FY | 158.01 Million TWD | 246.53% |
| 2018 Q4 | 24.69 Million TWD | -31.76% |
| 2018 Q3 | 36.19 Million TWD | -61.11% |
| 2018 Q2 | 93.07 Million TWD | 2195.83% |
| 2017 Q2 | 41.06 Million TWD | 1773.35% |
| 2017 FY | 45.6 Million TWD | 119.33% |
| 2017 Q4 | -15.99 Million TWD | -169.59% |
| 2017 Q3 | 22.98 Million TWD | -44.02% |
| 2017 Q1 | -2.45 Million TWD | 98.87% |
| 2016 FY | -235.93 Million TWD | -140.68% |
| 2016 Q4 | -217.33 Million TWD | -2043.12% |
| 2016 Q3 | -10.14 Million TWD | -2138.63% |
| 2016 Q2 | -453 Thousand TWD | 94.34% |
| 2016 Q1 | -8.01 Million TWD | 86.05% |
| 2015 FY | -98.02 Million TWD | 74.61% |
| 2015 Q1 | -26.53 Million TWD | 91.31% |
| 2015 Q2 | -25.09 Million TWD | 5.43% |
| 2015 Q3 | 11.01 Million TWD | 143.88% |
| 2015 Q4 | -57.41 Million TWD | -621.38% |
| 2014 FY | -386.15 Million TWD | -1350.07% |
| 2014 Q3 | -49.29 Million TWD | -105.85% |
| 2014 Q1 | -7.64 Million TWD | 72.87% |
| 2014 Q4 | -305.27 Million TWD | -519.3% |
| 2014 Q2 | -23.94 Million TWD | -213.4% |
| 2013 Q4 | -28.16 Million TWD | -293.98% |
| 2013 FY | 30.89 Million TWD | 6.93% |
| 2013 Q2 | 23.32 Million TWD | 9.93% |
| 2013 Q1 | 21.21 Million TWD | 317.69% |
| 2013 Q3 | 14.52 Million TWD | -37.74% |
| 2012 Q4 | -9.74 Million TWD | -122.78% |
| 2012 Q2 | 1.94 Million TWD | 130.25% |
| 2012 Q1 | -6.43 Million TWD | -301.41% |
| 2012 Q3 | 42.78 Million TWD | 2097.38% |
| 2012 FY | 28.89 Million TWD | -24.29% |
| 2011 Q2 | -23.68 Million TWD | -506.52% |
| 2011 Q1 | 5.82 Million TWD | -85.46% |
| 2011 FY | 38.15 Million TWD | -74.14% |
| 2011 Q4 | 3.19 Million TWD | -93.95% |
| 2011 Q3 | 52.82 Million TWD | 323.0% |
| 2010 Q2 | 37.69 Million TWD | -16.04% |
| 2010 Q1 | 44.89 Million TWD | 0.0% |
| 2010 FY | 147.54 Million TWD | 71.09% |
| 2010 Q4 | 40.08 Million TWD | 61.26% |
| 2010 Q3 | 24.85 Million TWD | -34.06% |
| 2009 FY | 86.23 Million TWD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Apex Biotechnology Corp. | 115.78 Million TWD | 71.506% |
| Sinphar Pharmaceutical Co.,Ltd. | 375.17 Million TWD | 91.206% |
| Panion & Bf Biotech Inc. | 77.21 Million TWD | 57.276% |
| Chunghwa Chemical Synthesis & Biotech Co., Ltd. | 264.9 Million TWD | 87.546% |
| Abnova (Taiwan) Corporation | 43.67 Million TWD | 24.468% |
| Adimmune Corporation | -639.89 Million TWD | 105.156% |
| Tanvex BioPharma, Inc. | -2.13 Billion TWD | 101.544% |
| Polaris Group | -1.57 Billion TWD | 102.092% |
| Energenesis Biomedical CO.,LTD. | -260.38 Million TWD | 112.67% |
| UnicoCell Biomed Co., Ltd. | -84.1 Million TWD | 139.225% |
| PELL Bio-Med Technology Co. Ltd. | -398.75 Million TWD | 108.273% |